CD33 and leukemia: Although efficacy was already achieved in clinical trials using CAR T cells directed against CD123 or combinations of CD33/CLL-1, these approaches will only benefit a minority of patients owing to their application as a bridge to transplant for avoiding profound on-target/off-leukemia activities [6, 7].